Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of ibrutinib given in combination with bendamustine and rituximab in patients 65 years of age or older with newly diagnosed mantle cell lymphoma.
| Category | Value |
|---|---|
| Date last updated at source | 2017-06-01 |
| Study type(s) | Interventional |
| Expected enrolment | 524 |
| Study start date | 2013-05-16 |
| Estimated primary completion date | 2021-10-10 |